The University of Southampton
University of Southampton Institutional Repository

Prognostic markers in chronic lympocytic leukaemia

Prognostic markers in chronic lympocytic leukaemia
Prognostic markers in chronic lympocytic leukaemia
Rai and Binet staging of chronic lymphocytic leukaemia (CLL) is being superseded by new prognostic markers. The mutational status of the immunoglobulin variable region heavy-chain genes segregates the disease into more benign and more malignant versions, and has been confirmed as an important prognostic marker in prospective clinical trials. A search for surrogate markers for this difficult-to-perform assay has led to flow cytometric assays for CD38 and ZAP-70 expression, although in both cases there are problems with standardization and interpretation of the assays. A separate pathway of research has revealed two chromosomal aberrations deletions of 11q and 17p - as important prognostic markers. Fluorescent in-situ hybridization has made their detection readily available. These five markers are in different stages of evaluation, but some of them are ready to be used for risk-adapted therapy in clinical trials. Other assays are in earlier stages of assessment.
time, high-risk, heavy-chain gene, igv(h) genes, gene, cd38, binet, expression, cll, cd38 expression, genomic aberrations, chronic lymphocytic-leukemia, del 17p, disease, variable-region mutations
1521-6926
455-468
Hamblin, Terry J.
57389613-7900-48fd-b3e6-8ca8fbdceccb
Hamblin, Terry J.
57389613-7900-48fd-b3e6-8ca8fbdceccb

Hamblin, Terry J. (2007) Prognostic markers in chronic lympocytic leukaemia. Best Practice and Research Clinical Haematology, 20 (3), 455-468. (doi:10.1016/j.beha.2007.02.001).

Record type: Article

Abstract

Rai and Binet staging of chronic lymphocytic leukaemia (CLL) is being superseded by new prognostic markers. The mutational status of the immunoglobulin variable region heavy-chain genes segregates the disease into more benign and more malignant versions, and has been confirmed as an important prognostic marker in prospective clinical trials. A search for surrogate markers for this difficult-to-perform assay has led to flow cytometric assays for CD38 and ZAP-70 expression, although in both cases there are problems with standardization and interpretation of the assays. A separate pathway of research has revealed two chromosomal aberrations deletions of 11q and 17p - as important prognostic markers. Fluorescent in-situ hybridization has made their detection readily available. These five markers are in different stages of evaluation, but some of them are ready to be used for risk-adapted therapy in clinical trials. Other assays are in earlier stages of assessment.

This record has no associated files available for download.

More information

Published date: September 2007
Keywords: time, high-risk, heavy-chain gene, igv(h) genes, gene, cd38, binet, expression, cll, cd38 expression, genomic aberrations, chronic lymphocytic-leukemia, del 17p, disease, variable-region mutations

Identifiers

Local EPrints ID: 62772
URI: http://eprints.soton.ac.uk/id/eprint/62772
ISSN: 1521-6926
PURE UUID: f41939f2-d3da-4a80-a551-65cb0cd6eaed

Catalogue record

Date deposited: 11 Sep 2008
Last modified: 15 Mar 2024 11:32

Export record

Altmetrics

Contributors

Author: Terry J. Hamblin

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×